Endurance-3: A Phase 3, Randomized, Open-Label, Active-Controlled Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered with Daclatasvir in Adults with HCV Genotype 3 Infection
Foster, G, Gane, E, Asatryan, A, Pol, S, Poordad, F, Vierling, J, Kort, J, Lin, C.-W, Lovell, S.S, Ng, T.I, Mensa, F
Published in Journal of hepatology (2016)
Published in Journal of hepatology (2016)
Get full text
Journal Article
High Svr Rates with ABT-493 + ABT-530 Co-Administered for 8 Weeks in Non-Cirrhotic Patients with HCV Genotype 3 Infection
Muir, A.J, Strasser, S, Wang, S, Shafran, S, Bonacini, M, Kwo, P, Wyles, D, Gane, E, Lovell, S.S, Lin, C.-W, Ng, T.I, Kort, J, Mensa, F.J
Published in Journal of hepatology (2016)
Published in Journal of hepatology (2016)
Get full text
Journal Article
High SVR Rates with the Combination of ABT-493 + ABT-530 for 8 Weeks in Non-Cirrhotic Patients with HCV Genotype 1 or 2 Infection
Poordad, F, Felizarta, F, Wang, S, Asatryan, A, Hassanein, T, Aguilar, H, Lalezari, J, Overcash, J.S, Ng, T.I, Lovell, S.S, Lin, C.-W, Kort, J, Mensa, F.J
Published in Journal of hepatology (2016)
Published in Journal of hepatology (2016)
Get full text
Journal Article
O163 TURQUOISE-II: SVR12 RATES OF 92–96% IN 380 HEPATITIS C VIRUS GENOTYPE 1-INFECTED ADULTS WITH COMPENSATED CIRRHOSIS TREATED WITH ABT-450/R/ABT-267 AND ABT-333 PLUS RIBAVIRIN (3D+RBV)
Poordad, F, Hezode, C, Trinh, R, Kowdley, K.V, Zeuzem, S, Agarwal, K, Shiffman, M.L, Wedemeyer, H, Berg, T, Yoshida, E.M, Forns, X, Lovell, S.S, Da Silva-Tillmann, B, Campbell, A.L, Podsadecki, T
Published in Journal of hepatology (01.04.2014)
Published in Journal of hepatology (01.04.2014)
Get full text
Journal Article
O58 RESULTS FROM THE PHASE 2 PEARL-I STUDY: INTERFERON-FREE REGIMENS OF ABT-450/R + ABT-267 WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HCV GENOTYPE 4 INFECTION
Hezode, C, Marcellin, P, Pol, S, Hassanein, T, Fleischer-Stepniewska, K, Baykal, T, Wang, T, Lovell, S.S, Pilot-Matias, T, Vilchez, R.A
Published in Journal of hepatology (01.04.2014)
Published in Journal of hepatology (01.04.2014)
Get full text
Journal Article
THU-482 - Endurance-3: A Phase 3, Randomized, Open-Label, Active-Controlled Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered with Daclatasvir in Adults with HCV Genotype 3 Infection
Foster, G., Gane, E., Asatryan, A., Pol, S., Poordad, F., Vierling, J., Kort, J., Lin, C.-W., Lovell, S.S., Ng, T.I., Mensa, F.
Published in Journal of hepatology (2016)
Published in Journal of hepatology (2016)
Get full text
Journal Article
PS098 - High Svr Rates with ABT-493 + ABT-530 Co-Administered for 8 Weeks in Non-Cirrhotic Patients with HCV Genotype 3 Infection
Muir, A.J., Strasser, S., Wang, S., Shafran, S., Bonacini, M., Kwo, P., Wyles, D., Gane, E., Lovell, S.S., Lin, C.-W., Ng, T.I., Kort, J., Mensa, F.J.
Published in Journal of hepatology (2016)
Published in Journal of hepatology (2016)
Get full text
Journal Article
SAT-157 - High SVR Rates with the Combination of ABT-493 + ABT-530 for 8 Weeks in Non-Cirrhotic Patients with HCV Genotype 1 or 2 Infection
Poordad, F., Felizarta, F., Wang, S., Asatryan, A., Hassanein, T., Aguilar, H., Lalezari, J., Overcash, J.S., Ng, T.I., Lovell, S.S., Lin, C.-W., Kort, J., Mensa, F.J.
Published in Journal of hepatology (2016)
Published in Journal of hepatology (2016)
Get full text
Journal Article